Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioMarin Pharmaceutical Inc. (BMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed rare disease biotechnology company, BioMarin files periodic and current reports that describe its financial condition, results of operations, governance changes and material corporate events.
Investors researching BMRN can review Forms 10-K and 10-Q for detailed discussions of BioMarin’s business, risk factors, rare disease portfolio and pipeline strategy. Current reports on Form 8-K, such as those announcing quarterly results, acquisitions, leadership changes or guidance updates, give insight into significant developments affecting the company’s Enzyme Therapies, Skeletal Conditions and gene therapy franchises.
Through this page, users can also track information that may appear in proxy materials and other filings, including board composition and committee appointments, executive roles and the company’s use of non-GAAP financial measures like Non-GAAP Operating Margin and Non-GAAP Diluted EPS, as described in its disclosures. For those monitoring corporate actions, merger agreements, or business development transactions, the related 8-K filings and exhibits are a primary source of official information.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping readers interpret long or technical documents. Real-time updates from EDGAR, combined with structured access to forms such as 10-K, 10-Q and 8-K, allow investors to follow BioMarin’s regulatory reporting history and understand how management communicates strategy, performance and risk to the market.
BioMarin Pharmaceutical Inc. reported that it has appointed Rashmi Ramchandani as Vice President, Chief Accounting Officer, effective January 19, 2026. In this role she will also become the company’s principal accounting officer, while Brian Mueller will remain Executive Vice President, Chief Financial Officer and principal financial officer.
Ramchandani brings more than two decades of accounting and finance experience, including senior roles at Gilead Sciences and Strava, and is a CPA with a BA in Accounting and Psychology. Her compensation package includes a $460,000 annual base salary, a $400,000 sign-on bonus, eligibility for an annual bonus targeted at 45% of base salary starting in 2026, and equity awards of restricted stock units valued at $1,050,000 and $400,000 plus stock options valued at $450,000, all subject to time-based vesting and continued service.
The sign-on bonus must be repaid if her employment ends within two years under most circumstances, and the company states she has no related party transactions requiring disclosure.
BioMarin Pharmaceutical Inc. reported Q3 2025 results showing steady sales but a GAAP loss driven by R&D charges. Total revenue was $776.1 million, up from $745.7 million a year ago. Product leaders were VOXZOGO $218.4M, VIMIZIM $182.8M, and PALYNZIQ $108.8M; ALDURAZYME delivered $53.7M and ROCTAVIAN $3.2M.
Operating expenses rose to $822.8 million as R&D reached $409.5M, reflecting a $221.0M acquired in-process R&D charge tied to the Inozyme transaction. The quarter posted a net loss of $30.7M (diluted EPS $(0.16)) versus net income of $106.1M (EPS $0.55) last year. Year‑to‑date, revenue was $2,346.7M with net income $395.5M (diluted EPS $2.04), supported by operating cash flow of $728.4M.
Liquidity remained strong with cash and cash equivalents $1,250.1M, short‑term investments $227.7M, and long‑term investments $512.9M. Total assets were $7.61B. The company has $600.0M of 1.25% convertible notes due 2027. BioMarin completed the Inozyme acquisition (total consideration $329.1M), adding late‑stage enzyme therapy BMN 401; management also plans to pursue options to divest ROCTAVIAN.
BioMarin Pharmaceutical Inc. announced financial results for the third quarter ended September 30, 2025. The company furnished a press release dated October 27, 2025 as Exhibit 99.1.
The press release is furnished and not deemed filed, and the company also included the cover page Inline XBRL data as Exhibit 104.
BioMarin Pharmaceuticals filed an 8-K disclosing its use and definition of Non-GAAP Diluted EPS and related Non-GAAP measures. The filing explains Non-GAAP Diluted EPS as Non-GAAP Income divided by Non-GAAP weighted-average diluted shares outstanding, and defines reconciling adjustments that may exclude amortization of intangible assets, stock-based compensation expense and certain other specified items, plus an estimated tax impact for those adjustments. The company says it uses both GAAP and Non-GAAP results internally to assess operating performance and guide business decisions in its core activities: discovery, development, manufacture, marketing and sale of biologic therapies. The filing cautions that these measures are not prepared under GAAP, have no standardized meaning, and may be calculated differently than similarly named metrics at other companies.
BioMarin Pharmaceutical insider Gregory R. Friberg, listed as Executive Vice President and Chief R&D Officer, reported a sale of 3,304 shares of BioMarin common stock on 09/30/2025 at a price of $54.16 per share. After the transaction, the reporting person beneficially owned 43,506 shares. The Form 4 was signed on 10/02/2025 by an attorney-in-fact.
Viking Global and affiliated funds report a 6.4% common-stock stake in BioMarin Pharmaceuticals (BMRN). Collectively the Reporting Persons beneficially own 12,288,611 shares out of 192,001,650 shares outstanding as of June 30, 2025. Ownership is shared (no reported sole voting or dispositive power); the holdings are held across several Viking entities and funds (largest positions reported: Viking Global Investors LP 12,288,611; Viking Global Performance LLC 8,208,825; Viking Global Equities Master Ltd. 8,044,650; Viking Long Fund Master Ltd. 2,856,671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115). The filing states the securities were not acquired to change or influence control of the issuer. Signatures on the amendment are dated August 14, 2025.
Primecap Management Co/CA filed an amendment to Schedule 13G reporting beneficial ownership of 15,795,383 shares of BioMarin Pharmaceutical Inc. common stock, equal to 8.24% of the class. The filing shows Primecap has sole voting power over 15,087,400 shares and sole dispositive power over 15,795,383 shares. The statement is for CUSIP 09061G101 and designates the security class as common stock. Item 10 certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is dated as an event on 06/30/2025 and signed on 08/13/2025.
BioMarin Pharmaceutical Inc. announced that Erin Burkhart, Group Vice President and Chief Accounting Officer, notified the company of her voluntary resignation effective
BioMarin Pharmaceutical Inc. (BMRN) – Form 4
On 08/01/2025, director Ian T. Clark was awarded 7,000 restricted stock units (RSUs) of BioMarin common stock, recorded with transaction code “A” (acquisition). Because RSUs are granted by the company, the stated price is $0.00 and no open-market cash outlay occurred. Following the grant, Clark’s direct beneficial ownership stands at 7,000 shares; no indirect holdings or derivative positions were reported. The filing contains no sales, options, or additional equity instruments.
The transaction represents routine director equity compensation rather than an opportunistic purchase, but it modestly increases insider alignment with shareholders. No earnings data, guidance changes, or other material corporate events accompany this filing.
FAQ
What is the current stock price of Biomarin Pharmaceutical (BMRN)?
What is the market cap of Biomarin Pharmaceutical (BMRN)?
